Effect of trimetazidine combined with remote ischemic preconditioning on myocardial damage and prognosis in elderly ischemic heart disease patients after percutaneous coronary intervention

Objective To investigate the effect of trimetazidine combined with remote ischemic preconditioning(RIPC) on myocardial damage and prognosis in elderly ischemic heart disease patients undergoing percutaneous coronary intervention(PCI). Methods A total of 96 elderly ischemic heart disease patients treated with PCI were randomly divided into observation group(48 cases) and control group(48 cases) from January,2016 to September,2016.All the patients of 3 groups received antiplatelet routine drug treatment,etc.The control group received additional trimetazidine therapy,while the observation group received additional trimetazidine and RIPC.The changes of cTnI and CK-MB before and after the treatment and the incidence of adverse cardiovascular events at follow-up of 6 months were observed in both groups. Results The levels of cTnI and CK-MB increased significantly in both groups at 24 h after treatment(P<0.05),the levels of cTnI and CK-MB of the observation group was significantly lower than that at 24 h after the treatment(P<0.05);6 months follow-up showed that there were 2 cases of recurrent angina in the observation group,with an incidence of 4.17%;there were no myocardial infarction and death cases;while there were 10 cases of recurrent angina in the control group with an incidence of 20.83%,there were 5 case of myocardial infarction with an incidence of 10.42%,there was no death case. The incidence of recurrent angina and myocardial infarction of the observation group was significantly lower than that in the control group(P<0.05). Conclusion Trimetazidine combined with remote ischemic preconditioning in elderly ischemic heart disease patients after PCI can obviously reduce the levels of cTnI and CK-MB,reduce the myocardial damage and incidence of adverse cardiovascular events.